Summary for the risk of neonatal hypoglycaemia for infants born to mothers with GDM

No conclusions possible: low‐ to very low‐quality evidence, or insufficient evidence to comment on the effectiveness, more evidence needed Moderate‐quality evidence showed no clear difference for the risk of neonatal hypoglycaemia (not defined) for babies born to mothers with GDM who were treated with lifestyle intervention versus usual care or diet alone Low‐quality evidence suggested a reduced risk of neonatal hypoglycaemia for babies born to mothers with GDM who were treated with myo‐inositol versus placebo (hypoglycaemia not defined). Low‐quality evidence showed no clear difference for metformin versus glibenclamide; insulin versus oral hypoglycaemic pharmacological therapies or managed with self‐ versus periodic‐glucose monitoring (hypoglycaemia not defined). Very low‐quality evidence showed no clear difference for glibenclamide versus acarbose (hypoglycaemia defined); exercise versus control (hypoglycaemia not defined); soy‐ versus no soy‐protein diet; intensive management versus routine care (hypoglycaemia defined); induction of labour versus expectant management; glibenclamide versus placebo; energy‐ diet versus no energy‐restricted diet; low‐ versus high‐carbohydrate diet; ethnic specific diet versus standard healthy diet (hypoglycaemia not defined); insulin type A versus B; insulin versus diet; insulin versus exercise; insulin regimen A versus B; telemedicine versus standard care for glucose monitoring or continuous‐ versus self‐monitoring blood glucose (hypoglycaemia defined)